Maze Therapeutics, Inc.
MAZE
$9.07
-$0.25-2.68%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 2.50M | 82.50M | 82.50M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 2.50M | 82.50M | 82.50M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 2.50M | 82.50M | 82.50M | -- |
| SG&A Expenses | 7.51M | 6.87M | 6.02M | 6.02M | 7.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.73M | 26.73M | 26.73M | 26.73M | 23.05M |
| Operating Income | -29.73M | -24.23M | 55.77M | 55.77M | -23.05M |
| Income Before Tax | -29.85M | -25.03M | 54.14M | 54.14M | -26.58M |
| Income Tax Expenses | -275.00K | -279.00K | 863.00K | 863.00K | -- |
| Earnings from Continuing Operations | -29.58M | -24.75M | 53.28M | 53.28M | -26.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.58M | -24.75M | 53.28M | 53.28M | -26.58M |
| EBIT | -29.73M | -24.23M | 55.77M | 55.77M | -23.05M |
| EBITDA | -29.02M | -23.44M | 56.67M | 56.67M | -22.08M |
| EPS Basic | -2.02 | -0.10 | 0.24 | 0.24 | -1.19 |
| Normalized Basic EPS | -7.25 | -0.60 | 1.55 | 1.55 | -0.63 |
| EPS Diluted | -2.31 | -0.10 | 0.17 | 0.17 | -1.19 |
| Normalized Diluted EPS | -7.25 | -0.60 | 1.12 | 1.12 | -0.63 |
| Average Basic Shares Outstanding | 2.43M | 23.41M | 22.79M | 22.79M | 22.39M |
| Average Diluted Shares Outstanding | 2.43M | 23.41M | 31.54M | 31.54M | 22.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
